ArticleJournal of neuro-oncology2013
Supratentorial gross-totally resected non-anaplastic ependymoma: population based patterns of care and outcomes analysis.
Article in Journal of neuro-oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 33 citations in OpenAlex.
- Long-term outcomes and late effects of surgery and radiotherapy in adult intracranial ependymoma patients.Journal of neuro-oncology · 2026Article
- Targeted and systemic therapies for recurrent adult ependymomas: real-world outcomes from a single institution and concise literature review.Frontiers in oncology · 2026Article
- Adult ependymoma: results from the Dutch Brain Tumour Registry on primary treatment and survival.Journal of neuro-oncology · 2025Article
- Prognostic factors of pediatric ependymomas at a National Cancer Reference Center in Peru.Frontiers in oncology · 2023Article
- Ependymoma: Evaluation and Management Updates.Current oncology reports · 2022Review
- Molecular testing for adolescent and young adult central nervous system tumors: A Canadian guideline.Frontiers in oncology · 2022Review
- Supratentorial cortical ependymoma: A systematic literature review and case illustration.Rare tumors · 2022Review
- An Overview of Intracranial Ependymomas in Adults.Cancers · 2021Review
- Intracranial ependymomas: The role of advanced neuroimaging in diagnosis and management.The neuroradiology journal · 2021Review
- Intraventricular neuroepithelial tumors: surgical outcome, technical considerations and review of literature.BMC cancer · 2020Observational
- Canadian Pediatric Neuro-Oncology Standards of Practice.Frontiers in oncology · 2020Article
- EANO guidelines for the diagnosis and treatment of ependymal tumors.Neuro-oncology · 2018Review
- The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants.Acta neuropathologica · 2017Article
- Toward an integrated histomolecular diagnosis of supratentorial ependymoma.Neuro-oncology · 2016Article
- Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients.Neuro-oncology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Observation following gross-total resection (GTR) for non-anaplastic supratentorial ependymomas is often advocated based on small, retrospective series. The purpose of this study is to perform a population-based analysis to examine outcomes for this rare cohort of low-risk patients. A retrospective analysis was conducted utilizing the Surveillance, Epidemiology and End Results Program of the United States National Cancer Institute. We identified patients with supratentorial non-anaplastic ependymoma who underwent GTR alone or GTR followed by radiation. We identified 92 patients who met these criteria. The median age was 17.5 years (range 1-83) with the majority female (58 %) and white (75 %). Radiotherapy (RT) was delivered in half of patients. The 5-/10-year Kaplan-Meier estimated overall survival (OS) and cause-specific survival (CSS) for the overall cohort was 83.2/71.4 and 84.1/78.0 %, respectively. There was no evidence of decreased CSS (HR 0.52 [0.18-1.51]; p = 0.23) or OS (HR 0.63 [0.25-1.59]; p = 0.33) with the omission of RT on univariate analysis. Age ≥18 years correlated with worse OS (HR 4.01 [1.45-11.11]; p = 0.008) and CSS (HR 2.86 [0.99-8.31]; p = 0.05). RT did not impact outcome for this low-risk cohort of patients. Older age correlates with poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.